在英格兰,对诊断肌痛性脑膜炎的机会不平等
Gemma Louise Samms1, Chris P Ponting2
1MRC Human Genetics Unit, The University of Edinburgh, Edinburgh, Scotland, EH4 2XU, UK.
BMC public health
|April 21, 2025
概括
肌痛性脑筋炎 (ME/CFS) 的诊断在少数民族群体中不成比例地低,在女性中更高. 这项研究估计英国的ME/CFS患病率较高,影响了社会经济负担评估.
科学领域:
- 医学研究 医学研究
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 肌痛性脑筋炎 (ME/CFS) 显著影响生活质量,没有治愈或确定的诊断测试.
- 准确的流行数据和了解诊断障碍对于公共卫生和政策至关重要.
- 现有的ME/CFS患病率估计因诊断不一致而有所不同.
研究的目的:
- 调查英格兰人口统计学中ME/CFS流行率和诊断差异.
- 确定影响ME/CFS诊断的因素,包括年龄,性别和种族.
- 为社会经济影响评估提供更准确的ME/CFS流行率估计.
主要方法:
- 从英格兰NHS (1989-2023) 获取的利用医院情节统计数据.
- 根据年龄,性别和种族分类的ICD-10代码G93.3 (反映ME/CFS症状) 的分层个体.
- 分析了NHS综合护理委员会 (ICB) 和全科医院的患病率变化.
主要成果:
- 100,055人被诊断患有ME/CFS (0.16%的患者);女性与男性的比例为3.88:1.
- 观察到患病率差异,白人被诊断出患病率是其他种族的五倍.
- 在少数民族群体,老年女性 (>60岁) 和老年男性 (>80岁) 中发现了显著的不足诊断.
结论:
- 少数民族,老年女性和男性,以及贫困地区的人,面临着ME/CFS不成比例的低诊断.
- 在英格兰,ME/CFS的估计终身患病率为女性0.92%,男性0.25%,在英国约为404,000人 (0.6%).
- 这种精细的流行率估计有助于评估ME/CFS的社会经济和疾病负担.
更多相关视频
10:50Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
7.6K
08:17Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
Published on: February 23, 2024
3.8K
相关概念视频
Myasthenia Gravis: Diagnostic Tests
538
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
538
Myasthenia Gravis: Overview and Treatment
958
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
958
